NCT05009680 - A Single and Repeat Dose Trial in Participants With Hepatic Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 4, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

GB1211

GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

DRUG

Placebo

Placebo is administered orally twice a day

Trial Locations (4)

COAMC Medical, Sofia

Gastroenterology Clinic, Lozenets district, Sofia

"Diagnostic-Advisory center 'ALEKSANDROVSKA Ltd", Sofia

University Multiprofile Hospital, Clinic of gastroenterology, Sofia